A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
COVID-19
CoronaVac
SARS-CoV-2
booster dose
phase III clinical trial
Journal
mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231
Informations de publication
Date de publication:
30 08 2022
30 08 2022
Historique:
pubmed:
11
8
2022
medline:
3
9
2022
entrez:
10
8
2022
Statut:
ppublish
Résumé
CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 and 4 weeks after two doses of CoronaVac; these levels were significantly reduced at 6 to 8 months after the two doses. Here, we report the effect of a booster dose of CoronaVac on the anti-SARS-CoV-2 immune response generated against the variants of concern (VOCs), Delta and Omicron, in adults participating in a phase III clinical trial in Chile. Volunteers immunized with two doses of CoronaVac in a 4-week interval received a booster dose of the same vaccine between 24 and 30 weeks after the second dose. Neutralization capacities and T cell activation against VOCs Delta and Omicron were assessed 4 weeks after the booster dose. We observed a significant increase in neutralizing antibodies 4 weeks after the booster dose. We also observed a rise in anti-SARS-CoV-2-specific CD4
Identifiants
pubmed: 35946814
doi: 10.1128/mbio.01423-22
pmc: PMC9426482
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0142322Subventions
Organisme : NIAID NIH HHS
ID : 75N93019C00065
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93021C00016
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
Nat Microbiol. 2022 Apr;7(4):524-529
pubmed: 35365787
Sci Immunol. 2021 Dec 24;6(66):eabl5344
pubmed: 34726470
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Lancet Infect Dis. 2021 Jun;21(6):803-812
pubmed: 33548194
N Engl J Med. 2022 Mar 17;386(11):1046-1057
pubmed: 35081293
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
Front Immunol. 2022 Jan 31;12:766278
pubmed: 35173705
Front Immunol. 2021 Nov 09;12:747830
pubmed: 34858404
Lancet Infect Dis. 2022 Apr;22(4):483-495
pubmed: 34890537
Lancet. 2022 Feb 5;399(10324):521-529
pubmed: 35074136
Lancet Infect Dis. 2022 Jan;22(1):56-63
pubmed: 34509185
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
Nat Med. 2022 Mar;28(3):481-485
pubmed: 35051990
Cell Res. 2022 Jan;32(1):103-106
pubmed: 34815511
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
N Engl J Med. 2021 Sep 2;385(10):875-884
pubmed: 34233097
Science. 2021 Oct 22;374(6566):eabj9853
pubmed: 34519540
Respirology. 2022 Apr;27(4):301-310
pubmed: 34820940
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
Vaccines (Basel). 2022 Jul 06;10(7):
pubmed: 35891246
Nature. 2021 Jun;594(7862):161-162
pubmed: 34089030
Front Immunol. 2021 Sep 29;12:742914
pubmed: 34659237
Cell Res. 2022 Jan;32(1):107-109
pubmed: 34862467
Clin Infect Dis. 2022 Aug 24;75(1):e792-e804
pubmed: 34537835
Nat Med. 2022 Mar;28(3):472-476
pubmed: 35042228